Thrombin activatable fibrinolysis inhibitor and thrombin-antithrombin-III- complex levels in patients with gastric cancer

Tumor Biology

Volumn 33, Issue 5, 2012, Pages 1519-1525

  Fidan, Evren ^a   Kavgaci, Halil ^a   Orem, Asim ^b   Yilmaz, Mustafa ^b   Yildiz, Bulent ^c   Fidan, Sami ^b   Akcan, Buket ^b   Ozdemir, Feyyaz ^a   Aydin, Fazil ^a  

^a KARADENIZ TECHNICAL UNIVERSITY   (Turkey)

^b KARADENIZ TECHNICAL UNIVERSITY   (Turkey)

^c ESKISEHIR OSMANGAZI UNIVERSITY   (Turkey)

Author keywords

Gastric cancer; TAFI; Thrombin antithrombin complex

Indexed keywords

D DIMER; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; THROMBIN ANTITHROMBIN COMPLEX; THROMBIN ANTITHROMBIN III COMPLEX; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLEEDING; CANCER CLASSIFICATION; CANCER PROGNOSIS; CANCER STAGING; CASE CONTROL STUDY; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; STOMACH CANCER; THROMBOSIS;

EID: 84868127434     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-012-0403-6     Document Type: Article

References (31)

1. Kvolik S, Jukic M, Matijevic M, Marjanovic K, Glavas-Obrovac L. An overview of coagulation disorders in cancer patients. Surg Oncol. 2010;19(1):e33-46.
2. De Cicco M. The prothrombotic state in cancer: pathogenic mechanisms. Crit Rev Oncol Hematol. 2004;50(3):187-96.
3. Bouma BN, Marx PF, Mosnier LO, Meijers JC. Thrombin-activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U). Thromb Res. 2001;101(5):329-54.
4. Bajzar L, Nesheim ME, Tracy PB. The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent. Blood. 1996;88(6):2093-100.
5. Bouma BN, Mosnier LO. Thrombin activatable fibrinolysis inhibitor (TAFI)how does thrombin regulate fibrinolysis? Ann Med. 2006;38(6):378-88.
6. Bajzar L. Thrombin activatable fibrinolysis inhibitor and an antifibrinolytic pathway. Arterioscler Thromb Vasc Biol. 2000;20(12):2511-8.
7. Fujimoto H, Gabazza EC, Hataji O, Yuda H, D'Alessandro-Gabazza CN, Nakano M, Franco OE, Hayashi T, Suzuki K, Adachi Y, Taguchi O. Thrombin-activatable fibrinolysis inhibitor and protein C inhibitor in interstitial lung disease. Am J Respir Crit Care Med. 2003;167(12):1687-94.
8. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61:69.
9. Siewert JR, Böttcher K, Stein HJ, Roder JD. Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study. Ann Surg. 1998;228(4):449-61.
10. Nakamura K, Ueyama T, Yao T, et al. Pathology and prognosis of gastric carcinoma. Findings in 10,000 patients who underwent primary gastrectomy. Cancer. 1992;70(5):1030-7.
11. Francis JL, Biggerstaff J, Amirkhosravi A. Hemostasis and malignancy. Semin Thromb Hemost. 1998;24(2):93-109.
12. Hataji O, Taguchi O, Gabazza EC, Yuda H, D'Alessandro-Gabazza CN, Fujimoto H, Nishii Y, Hayashi T, Suzuki K, Adachi Y. Increased circulating levels of thrombin-activatable fibrinolysis inhibitor in lung cancer patients. Am J Hematol. 2004;76(3):214-9.
13. Kovacova E, Kinova S, Duris I, Remkova A. General changes in hemostasis in gastric cancer. Bratisl Lek Listy. 2009;110(4):215-21.
14. Lip GY, Chin BS, Blann AD. Cancer and the prothrombotic state. Lancet Oncol. 2002;3(1):27-34.
15. Goad KE, Gralnick HR. Coagulation disorders in cancer. Hematol Oncol Clin N Am. 1996;10(2):457-84.
16. Edwards RL, Rickles FR, Moritz TE, Henderson WG, Zacharski LR, Forman WB, Cornell CJ, Forcier RJ, O'Donnell JF, Headley E, et al. Abnormalities of blood coagulation tests in patients with cancer. Am J Clin Pathol. 1987;88(5):596-602.
17. Kaftan O, Kasapoglu B, Koroglu M, Kosar A, Yalcin SK. Thrombin-activatable fibrinolysis inhibitor in breast cancer patients. Med Princ Pract. 2011;20(4):332-5.
18. Ikeda M, Furukawa H, Imamura H, Shimizu J, Ishida H, Masutani S, Tatsuta M, Satomi T. Poor prognosis associated with thrombocytosis in patients with gastric cancer. Ann Surg Oncol. 2002;9(3):287-91.
19. Lopes A, Daras V, Cross PA, Robertson G, Beynon G, Monaghan JM. Thrombocytosis as a prognostic factor in women with cervical cancer. Cancer. 1994;74(1):90-2.
20. Pedersen LM, Milman N. Prognostic significance of thrombocytosis in patients with primary lung cancer. Eur Respir J. 1996;9(9):1826-30.
21. Di Micco P, Romano M, Niglio A, Nozzolillo P, Federico A, Petronella P, Nunziata L, Di Micco B, Torella R. Alteration of haemostasis in non-metastatic gastric cancer. Dig Liver Dis. 2001;33(7):546-50.
22. Ferrigno D, Buccheri G, Ricca I. Prognostic significance of blood coagulation tests in lung cancer. Eur Respir J. 2001;17(4):667-73.
23. Kwon HC, Oh SY, Lee S, Kim SH, Han JY, Koh RY, Kim MC, Kim HJ. Plasma levels of prothrombin fragment F1 + 2, D-dimer and prothrombin time correlate with clinical stage and lymph node metastasis in operable gastric cancer patients. Jpn J Clin Oncol. 2008;38(1):2-7.
24. Yigit E, Gönüllü G, Yücel I, Turgut M, Erdem D, Cakar B. Relation between hemostatic parameters and prognostic/predictive factors in breast cancer. Eur J Intern Med. 2008;19(8):602-7.
25. Batschauer AP, Figueiredo CP, Bueno EC, Ribeiro MA, Dusse LM, Fernandes AP, Gomes KB, Carvalho MG. D-dimer as a possible prognostic marker of operable hormone receptor-negative breast cancer. Ann Oncol. 2010;21(6):1267-72.
26. Pavey SJ, Hawson GA, Marsh NA. Alterations to the fibrinolytic enzyme system in patients with non-small cell lung carcinoma. Blood Coagul Fibrinolysis. 1999;10(5):261-7.
27. Ozyilkan O, Baltali E, Ozdemir O, Tekuzman G, Kirazli S, Firat D. Haemostatic changes; plasma levels of alpha2-antiplasmin-plasmin complex and thrombin-antithrombin III complex in female breast cancer. Tumori. 1998;84(3):364-7.
28. Seitz R, Heidtmann HH, Wolf M, Immel A, Egbring R. Prognostic impact of an activation of coagulation in lung cancer. Ann Oncol. 1997;8(8):781-4.
29. Zacharski LR. Anticoagulants in cancer treatment: malignancy as a solid phase coagulopathy. Cancer Lett. 2002;186(1):1-9.
30. Meijers JC, Oudijk EJ, Mosnier LO, Bos R, Bouma BN, Nieuwenhuis HK, Fijnheer R. Reduced activity of TAFI (thrombin-activatable fibrinolysis inhibitor) in acute promyelocytic leukaemia. Br J Haematol. 2000;108(3):518-23.
31. Masago K, Fujita S, Mio T, Togashi Y, Kim YH, Hatachi Y, Fukuhara A, Irisa K, Sakamori Y, Mishima M. Clinical significance of the ratio between the alpha 2 plasmin inhibitor-plasmin complex and the thrombin-antithrombin complex in advanced non-small cell lung cancer. Med Oncol. 2011;28(1):351-6.